Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvoxamine for Long COVID-19
NCT05874037Phase 3Completed
- Sponsor
- Washington University School of Medicine
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluvoxamine in post-COVID-19 condition (PCC), sponsored by Washington University School of Medicine. Started May 2023; status: completed.
02
Drugs
fluvoxamine
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT05874037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874037.